Oliver Lagore Vanvalin Investment Group bought a new stake in Boston Scientific Co. (NYSE:BSX – Get Rating) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 750 shares of the medical equipment provider’s stock, valued at approximately $34,000.
Other hedge funds also recently modified their holdings of the company. Concorde Financial Corp bought a new position in shares of Boston Scientific in the 4th quarter valued at about $34,000. Acadian Asset Management LLC bought a new position in Boston Scientific during the 1st quarter worth approximately $35,000. Quent Capital LLC bought a new position in Boston Scientific during the 4th quarter worth approximately $35,000. Nauset Wealth Management. LLC bought a new position in Boston Scientific during the 1st quarter worth approximately $37,000. Finally, JFS Wealth Advisors LLC boosted its stake in Boston Scientific by 43.6% during the 1st quarter. JFS Wealth Advisors LLC now owns 994 shares of the medical equipment provider’s stock worth $44,000 after acquiring an additional 302 shares during the last quarter. Institutional investors own 90.33% of the company’s stock.
Insider Buying and Selling
In related news, EVP Wendy Carruthers sold 7,500 shares of the business’s stock in a transaction on Monday, July 18th. The shares were sold at an average price of $38.00, for a total transaction of $285,000.00. Following the transaction, the executive vice president now directly owns 124,913 shares in the company, valued at $4,746,694. The sale was disclosed in a filing with the SEC, which is available through this link. In other Boston Scientific news, EVP Wendy Carruthers sold 7,500 shares of the company’s stock in a transaction on Monday, July 18th. The shares were sold at an average price of $38.00, for a total value of $285,000.00. Following the transaction, the executive vice president now directly owns 124,913 shares in the company, valued at $4,746,694. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Eric Francis Yves Thepaut sold 20,676 shares of the company’s stock in a transaction on Monday, August 1st. The shares were sold at an average price of $40.99, for a total transaction of $847,509.24. Following the completion of the transaction, the executive vice president now owns 72,486 shares in the company, valued at $2,971,201.14. The disclosure for this sale can be found here. Over the last three months, insiders have sold 66,764 shares of company stock worth $2,718,248. Insiders own 0.71% of the company’s stock.
Wall Street Analysts Forecast Growth
Boston Scientific Price Performance
NYSE BSX opened at $41.70 on Friday. The company has a quick ratio of 0.86, a current ratio of 1.31 and a debt-to-equity ratio of 0.51. Boston Scientific Co. has a 12-month low of $34.98 and a 12-month high of $47.49. The company has a market capitalization of $59.61 billion, a PE ratio of 72.76, a price-to-earnings-growth ratio of 2.28 and a beta of 0.85. The firm’s 50 day moving average is $40.43 and its 200-day moving average is $40.95.
Boston Scientific (NYSE:BSX – Get Rating) last posted its quarterly earnings data on Wednesday, July 27th. The medical equipment provider reported $0.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.42 by $0.02. The company had revenue of $3.24 billion for the quarter, compared to the consensus estimate of $3.22 billion. Boston Scientific had a net margin of 7.16% and a return on equity of 14.58%. The firm’s revenue was up 5.4% compared to the same quarter last year. During the same period last year, the company earned $0.40 earnings per share. Equities research analysts anticipate that Boston Scientific Co. will post 1.76 earnings per share for the current fiscal year.
Boston Scientific Company Profile
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems.
- Get a free copy of the StockNews.com research report on Boston Scientific (BSX)
- 3 Banks Worth Considering For Q4
- Stock Market: 3 Islands Of Strength In A Sea Of Red
- MarketBeat: Week in Review 9/12 – 9/16
- No One Told These 3 Stocks It’s a Down Week
- Is There a Cure for What is Ailing Teladoc Stock?
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.